Best Stocks to Buy in June for Long-Term Upside: Veeva Systems

Why It Matters

The deep discount combined with a cash‑rich, debt‑free balance sheet and a strategic AI/CRM transition could generate outsized long‑term returns, while underscoring the accelerating digitization of the life‑sciences sector.

Key Takeaways

• Veeva down ~45% from 2021 peak, implying ~80% upside.
• FY27 revenue forecast $4.01 billion, about 13% year‑over‑year growth.
• Cash balance $6.6 billion and zero debt enable AI expansion.
• Migrating customers to Vault CRM replaces legacy Salesforce‑based platform.
• Zacks average price target shows ~45% upside with double‑digit earnings growth.

Pulse Analysis

The life‑sciences cloud market has become a battleground for specialized software firms, and Veeva Systems sits at the core of this shift. By delivering end‑to‑end solutions—from R&D and clinical trials to regulatory compliance—Veeva has captured a sizable share of a $30 billion industry that values data integrity and speed. Its decision to decouple from Salesforce and launch the Vault CRM platform signals a broader trend: niche players are building proprietary ecosystems to outpace generic enterprise solutions, positioning themselves for higher margins and deeper client lock‑in.

Financially, Veeva’s profile is unusually robust for a high‑growth tech stock. The company generated $3.20 billion in FY26 revenue and is on track for $4.01 billion in FY27, reflecting a 13% year‑over‑year increase. Earnings are projected to expand double‑digit through FY28, supported by a 30% YoY rise in free cash flow and a balance sheet boasting $6.6 billion in cash with zero debt. This liquidity gives Veeva the flexibility to invest aggressively in AI‑enhanced modules, pursue strategic acquisitions, and weather competitive pressures without compromising shareholder value.

For investors, Veeva presents a compelling risk‑adjusted opportunity. The stock trades at roughly 80% below its 2021 peak, translating to an estimated 80% upside if it returns to prior highs, while Zacks analysts peg a more conservative 45% upside based on earnings momentum. The primary headwinds include intensifying competition from Salesforce and the broader AI disruption that could reshape enterprise software demand. Nonetheless, Veeva’s strong cash position, ongoing product innovation, and expanding client base of top pharmaceutical firms suggest that the company is well‑positioned to capitalize on the digital transformation of drug development, making it a noteworthy candidate for long‑term portfolios.